Teleflex (NYSE:TFX) Given New $170.00 Price Target at Needham & Company LLC

Teleflex (NYSE:TFX) had its price objective boosted by stock analysts at Needham & Company LLC from $159.00 to $170.00 in a research note issued on Tuesday, MarketBeat.com reports. The brokerage currently has a “buy” rating on the medical technology company’s stock. Needham & Company LLC’s target price suggests a potential upside of 22.91% from the stock’s current price.

Several other analysts have also recently commented on TFX. UBS Group boosted their price target on Teleflex from $145.00 to $158.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 11th. Weiss Ratings restated a “sell (d)” rating on shares of Teleflex in a report on Wednesday, June 24th. Wall Street Zen raised shares of Teleflex from a “sell” rating to a “hold” rating in a research note on Sunday, August 9th. Piper Sandler reaffirmed an “overweight” rating and set a $169.00 target price (up from $160.00) on shares of Teleflex in a report on Friday, August 7th. Finally, Wells Fargo & Company raised their price target on shares of Teleflex from $130.00 to $138.00 and gave the stock an “equal weight” rating in a research note on Friday, May 8th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, six have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $152.90.

Teleflex Trading Down 0.4%

Shares of Teleflex stock opened at $138.31 on Tuesday. The company has a current ratio of 2.60, a quick ratio of 2.12 and a debt-to-equity ratio of 0.94. Teleflex has a twelve month low of $100.18 and a twelve month high of $145.00. The firm has a market capitalization of $5.86 billion, a PE ratio of -5.94, a P/E/G ratio of 0.93 and a beta of 0.81. The firm’s 50-day moving average price is $132.87 and its 200 day moving average price is $125.13.

Teleflex (NYSE:TFX) last posted its quarterly earnings data on Thursday, August 6th. The medical technology company reported $1.76 EPS for the quarter, topping the consensus estimate of $1.28 by $0.48. The company had revenue of $570.33 million during the quarter, compared to analyst estimates of $559.59 million. Teleflex had a positive return on equity of 11.93% and a negative net margin of 39.67%.Teleflex’s quarterly revenue was up 28.9% on a year-over-year basis. During the same period in the previous year, the business earned $3.73 EPS. Teleflex has set its FY 2026 guidance at 6.900-7.200 EPS. On average, sell-side analysts predict that Teleflex will post 7.26 EPS for the current fiscal year.

Institutional Trading of Teleflex

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Hsbc Holdings PLC raised its holdings in shares of Teleflex by 4.7% during the 1st quarter. Hsbc Holdings PLC now owns 1,861 shares of the medical technology company’s stock worth $222,000 after acquiring an additional 84 shares during the period. Banque Cantonale Vaudoise grew its holdings in shares of Teleflex by 82.5% in the fourth quarter. Banque Cantonale Vaudoise now owns 250 shares of the medical technology company’s stock valued at $31,000 after purchasing an additional 113 shares during the period. Hantz Financial Services Inc. grew its holdings in shares of Teleflex by 40.5% in the fourth quarter. Hantz Financial Services Inc. now owns 392 shares of the medical technology company’s stock valued at $48,000 after purchasing an additional 113 shares during the period. UMB Bank n.a. increased its position in Teleflex by 57.1% during the fourth quarter. UMB Bank n.a. now owns 311 shares of the medical technology company’s stock worth $38,000 after purchasing an additional 113 shares during the last quarter. Finally, Maryland State Retirement & Pension System increased its position in Teleflex by 1.5% during the fourth quarter. Maryland State Retirement & Pension System now owns 8,652 shares of the medical technology company’s stock worth $1,056,000 after purchasing an additional 129 shares during the last quarter. 95.62% of the stock is owned by institutional investors and hedge funds.

Teleflex Company Profile

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.